Intrinsiqq
Olema Pharmaceuticals Inc. logo

Olema Pharmaceuticals Inc. Insider Trading

OLMA

Compare
Last 12 months

Insiders sold $24.7M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Director Ian T Clark sold $7.87M on Dec 19, 2025, 100% of their stake, outside a plan. The last open-market buy by an executive or director was in Dec 2024.

Net open-market
−$24.7M
0 buys · 10 sales
Under a 10b5-1 plan
0%
of the value sold
Insiders who bought / sold
0 / 6
executives and directors
Last open-market buy
Dec 2024
Dec 17, 2024

Get an email when OLMA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Jul 23 – 24No plan
    Cyrus Harmon
    Director · sold 25,000 at avg $11.65
    291K
    3.0% of stake
  • Mar 3 – 4No plan
    Shawnte Mitchell
    Chief Legal Officer · sold 40,000 at avg $23.79
    952K
    99% of stake
  • Jan 20No plan
    Cyrus Harmon
    Director · sold 10,000 at $26.88
    269K
    1.2% of stake
  • Jan 13 – 15No plan
    Shane William Charles Kovacs
    Ch. Operating & Financial Off. · sold 103,822 at avg $28.70
    $2.98M
    43% of stake
  • Jan 14No plan
    Cyrus Harmon
    Director · sold 3,489 at $29.12
    102K
    0.4% of stake
  • Jan 12 – 14No plan
    David C. Myles
    Ch. Discov. & Non-clin Dev Off · sold 110,000 at avg $28.25
    $3.11M
    14% of stake
  • Dec 19, 2025 – Dec 23, 2025No plan
    Naseem Zojwalla
    Chief Medical Officer · sold 269,509 at avg $27.94
    $7.53M
    98% of stake
  • Dec 22, 2025No plan
    Cyrus Harmon
    Director · sold 2,881 at $28.53
    82K
    0.3% of stake
  • Dec 19, 2025No plan
    David C. Myles
    Ch. Discov. & Non-clin Dev Off · sold 51,000 at avg $30.46
    $1.55M
    8.4% of stake
  • Dec 19, 2025No plan
    Ian T Clark
    Director · sold 264,800 at avg $29.73
    $7.87M
    100% of stake
  • Sep 16, 2025 – Sep 18, 2025No plan
    Cyrus Harmon
    Director · sold 25,000 at avg $8.19
    205K
    2.8% of stake
  • Jan 8, 2025
    Bain Capital Life Sciences Investors, LLC
    Large holder · bought 300,000 at $5.76
    $1.73M
    7.5% of stake
  • Dec 17, 2024
    G. Walmsley Graham
    Director · bought 700,761 at $6.75
    $4.73M
    33% of stake
  • Dec 17, 2024No plan
    G. Walmsley Graham
    Director · sold 700,761 at $6.75
    $4.73M
    33% of stake
  • Dec 13, 2024
    G. Walmsley Graham
    Director · bought 700,761 at $6.75
    $4.73M
    New position
  • Dec 13, 2024No plan
    G. Walmsley Graham
    Director · sold 700,761 at $6.75
    $4.73M
    50% of stake
  • Dec 10, 2024 – Dec 11, 2024No plan
    Cyrus Harmon
    Director · sold 16,393 at avg $9.03
    148K
    1.8% of stake
  • Dec 10, 2024 – Dec 11, 2024No plan
    David C. Myles
    Ch. Discov. & Non-clin Dev Off · sold 26,066 at avg $9.01
    235K
    3.3% of stake
  • Dec 10, 2024 – Dec 11, 2024No plan
    Naseem Zojwalla
    Chief Medical Officer · sold 27,805 at avg $9.01
    250K
    19% of stake
  • Dec 10, 2024 – Dec 11, 2024No plan
    Shane William Charles Kovacs
    Ch. Operating & Financial Off. · sold 35,159 at avg $9.01
    317K
    6.1% of stake
  • Dec 10, 2024 – Dec 11, 2024No plan
    Sean Bohen
    President and CEO · sold 109,502 at avg $9.01
    986K
    31% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch OLMA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with OLMA

CompareIntrinsic value
OVIDOvid Therapeutics Inc.
$2.20-5.98%10
UPBUpstream Bio, Inc.
$1.59-20.50%21
LQDALiquidia Corporation
$54.43-3.88%63
PCRXPacira BioSciences Inc.
$36.48+0.00%61
SRPTSarepta Therapeutics Inc.
$13.33-5.93%58
ETONEton Pharmaceuticals Inc.
$60.85-0.83%75
ZBIOZenas BioPharma, Inc.
$23.85-4.75%10
AGIOAgios Pharmaceuticals Inc.
$27.60-4.03%40

Held by ETFs

OLMA is in 29 US ETFs. The largest of them, with OLMA's weight in each:

Spot a number that looks wrong? Check it in OLMA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing OLMA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.